Sun Pharma Announces US FDA Acceptance Of Supplemental Biologics License (Sbla) Application For ILUMYA® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis. If the sBLA is ...

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

AJMC: Please describe the process for the treatment of psoriasis currently at your health system, Emory Healthcare. What guidelines/pathways are involved? HAUMSCHILD: Our psoriasis treatment approach ...

Risankizumab is effective through 2.5 years of treatment among patients with psoriasis, with most patients achieving rapid and sustained response.

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants showed ...

MARIETTA, Ga. - Greg Morrison of Marietta has been living with plaque psoriasis for more than 30 years. "The rash, it itches constantly," Morrison says. "It flakes. It kind of pinches you, and then ...

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...

Learn how psoriasis, allergies, and eczema are connected and how they're different. Get lifestyle tips on managing both.